(Q40904060)

24 September 2017

title

Valaciclovir: development, clinical utility and potential (English)

1 reference

24 September 2017

Patel R

1

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

Expert Opinion on Investigational Drugs

24 September 2017

published in

1 reference

24 September 2017

volume

6

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

173-189

1 reference

Acyclovir: A Decade Later

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

The biochemistry and mechanism of action of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Cytomegalovirus retinitis and acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Preclinical development of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Chemotherapy of varicella zoster virus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Virus drug-resistance: mechanisms and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Pharmacokinetics of new antiherpetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Clinical pharmacokinetics of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

The natural history of herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Treatment of Interstitial Pneumonitis Due to Cytomegalovirus with Ganciclovir and Intravenous Immune Globulin: Experience of European Bone Marrow Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

HUS and TTP: variable expression of a single entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.2.173

21 January 2018

Identifiers

DOI

10.1517/13543784.6.2.173

1 reference

24 September 2017

1 reference